Edition:
Deutschland

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

67.80EUR
19 Feb 2019
Change (% chg)

€-0.36 (-0.53%)
Prev Close
€68.16
Open
€67.83
Day's High
€68.86
Day's Low
€67.59
Volume
1,943,420
Avg. Vol
3,506,883
52-wk High
€103.74
52-wk Low
€58.34

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Buy/Sell

Sell Hold Buy
1.81 Mean rating from 26 analysts

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Merck's Keytruda fails late-stage study in liver cancer patients

Feb 19 Merck & Co Inc said on Tuesday its cancer drug Keytruda failed the main goals of a late-stage trial and did not extend life of patients with a type of liver cancer.

German stocks - Factors to watch on Feb. 19

BERLIN/FRANKFURT, Feb 19 The following are some of the factors that may move German stocks on Tuesday:

RPT-German stocks - Factors to watch on Feb. 18

BERLIN/FRANKFURT, Feb 18 The following are some of the factors that may move German stocks on Monday:

German stocks - Factors to watch on Feb. 18

BERLIN/FRANKFURT, Feb 18 The following are some of the factors that may move German stocks on Monday:

Photo

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

Photo

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

UPDATE 1-Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

* Bayer gains full control over drug Vitrakvi (larotrectinib)

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT, Feb 15 German drugmaker Bayer acquired all rights it does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly's Loxo Oncology.

France suggests glyphosate exit could be even slower than planned

PARIS, Feb 15 Only half of France's farmland could do without glyphosate-based weed-killers by 2021, the country's farm minister suggested, further lowering an initial ambition to get rid of the controversial chemical by then.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.86%
Rohstoffe +0.15%
Industrie +0.35%
Konjunktur abhängige Waren & Dienstleistungen +0.37%
Konjunktur unabhängige Waren & Dienstleistungen +0.23%
Finanzindustrie -0.26%
Pharma +0.13%
Technologie +0.33%
Telekommunikation +0.62%